What is LL-37?
LL-37 is a 37-residue human cathelicidin peptide studied in host defense, inflammatory signaling and wound biology. Synthetic LL-37 has also been tested in specific topical clinical formulations.
Mechanism & research focus
It has antimicrobial and immune-signaling activities. Primary experiments showed leukocyte recruitment through FPRL1-associated signaling; its biological effects are broader than a single antimicrobial mechanism.
What the research covers
A larger phase IIb trial in 148 patients with difficult-to-heal venous leg ulcers found no significant overall healing improvement with LL-37 compared with placebo alongside compression therapy. A post hoc subgroup finding in larger wounds was exploratory.
What remains uncertain
The overall negative result must not be replaced by the favorable subgroup interpretation. Topical ulcer studies do not validate systemic treatment or use for unrelated infections. Human efficacy, exposure and safety depend on the specific formulation and clinical setting.
The evidence label describes the linked research, not the suitability of a catalog product for use in people. Formulation, identity, purity, and measured content must be assessed separately.
Sources & studies
LL-37 recruits human leukocytes through FPRL1 ↗
Chemotaxis and calcium-signaling experiments in immune cells and receptor-expressing cells.
LL-37 in hard-to-heal venous leg ulcers: randomized placebo-controlled trial ↗
No significant healing benefit in the complete cohort; favorable subgroup analysis was post hoc.
Read the full paper for its design, controls and limitations. A source link is not a claim that its tested material matches a DA formulation.
Catalog formats & documentation
Formats grouped by compound identity. Availability and batch documentation remain on Disguised Alpha.
Original DA reference: LL-37 research guide ↗